Intersection
of Big Data and Academic Oncology Research – a Reality Check
The MedicRes Congress is a great opportunity to
combine different areas of medical research and will give an insight in the big
machinery producing the data on which treatment schedules are changing in
different therapy areas.
Big data in medical research and health care comes
with big promises and expectations. My talk shall reflect on the some of the
current realities of big date-oncology interaction from the perspective of an
academically minded sponsor organization. Additionally, I will formulate our
expectations of big data and outline development which may shape clinical
oncology in the future.
First, I will briefly describe our role as
academic sponsor for oncologic trials and our role as a direct and indirect creator
of big data; discuss the motivation and the way our data is used. I will then
present some select big data sources (e.g cancer registries, drug safety data
bases, electronic patient files) describe how they shape and influence our work
today and in the near future. I will describe the way we are producing data and
how big data can influence or improve the patient treatment by reducing costs
for running expensive trials. The last part of the talk will critically reflect
on big data initiatives in oncology in general and I shall take the opportunity
to comment on our expectations on what big data should achieve.
I call upon my colleagues to join the discussion
on big data in medical research and to take the opportunity to shape the
discourse.
October 19th, 15.30-17.00
The Cooper Union, The Great Hall 7 East 7th Street ,New York, NY 10003
“Big Data in Oncology Research” , Aysun Karatas , Chief Executive Officer AIO-Studien-
gGmbH (AIO Working Group of Medical Oncology within the German Cancer Society DKG)
Berlin Area, Germany
gGmbH (AIO Working Group of Medical Oncology within the German Cancer Society DKG)
Berlin Area, Germany
